PGNX: Progenics Pharmaceuticals Inc. is a Sell

The current rating for PGNX is 47, which is 6% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.